Trial Information

Only patients who meet the inclusion and exclusion criteria will be enrolled. The estimated
recruitment duration is 1 year. Imatinib will be given in the dose of 400 mg orally each day
unless disease progression or intolerance. The follow-up is 12 months.

Forty-eight subjects will be recruited for this study. This sample size is justified by the
number of patients required to establish an improvement in PFS with statistical significance
compared to historical control.

The standardized RECIST (Response Evaluation Criteria in Solid Tumors) method of
unidimensional tumor assessment will be employed to evaluate tumor lesion size per 2 months
in the determination of response rate and progression free survival. Repeated radiographic
assessment at 4 week intervals is consistent with general oncological practice associated
with computerized tomography (CT) or magnetic resonance imaging (MRI) scan testing. All
efficacy endpoints will be evaluated by the investigator.

Safety will be characterized in terms of the incidence, timing, severity, and relatedness of
adverse events and laboratory abnormalities. Severity will be graded according to the NCI
CTCAE Version 3.0.

Inclusion Criteria:

1. Histologically confirmed melanoma with metastases and has no received any systemic
treatment within 1 month

2. Evidence of mutations and/or copy number increases of KIT with laboratory examination
documented from either primary or metastatic tumor site

Start Date:

Completion Date:

Related Keywords:

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.